Salmeterol: Difference between revisions
ClaireLewis (talk | contribs) |
ClaireLewis (talk | contribs) |
||
| (One intermediate revision by one other user not shown) | |||
| Line 33: | Line 33: | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
*Long-acting beta-2 agonist, stimulates adenyl | *Long-acting beta-2 agonist, stimulates adenyl cyclase→ increased levels of cyclic AMP→ bronchial smooth muscle relaxation | ||
==Comments== | ==Comments== | ||
| Line 43: | Line 43: | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category:Pulmonology]] | |||
Latest revision as of 22:21, 23 September 2019
Administration
- Type: Beta-2 agonist, bronchodilator
- Dosage Forms:
- Routes of Administration: Inhalation
- Common Trade Names:
Adult Dosing
- 1 oral inhalation (50mcg) q12h
Pediatric Dosing
- >4yo: 1 oral inhalation (50mcg) q12h
Special Populations
- Pregnancy Rating: C
- Lactation risk: Infant risk cannot be ruled out
- Renal dosing: no adjustment
- Hepatic dosing: no adjustment
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Severe asthma exacerbation, asthma-related death
- Prolonged QT interval
Common
- Musculoskeletal pain
- Headache
Pharmacology
- Half-life: 5.5h
- Metabolism: Hepatic
- Excretion: Mostly fecal
Mechanism of Action
- Long-acting beta-2 agonist, stimulates adenyl cyclase→ increased levels of cyclic AMP→ bronchial smooth muscle relaxation